Thomson Reuters management commentary attributes Q3 2026 operating profit decline of 22% mainly to prior-year Elite stake sale gain
Bitget2026/11/04 22:16- Thomson Reuters management commentary attributed third-quarter 2026 operating profit's 22% decline to USD 402 million primarily to the prior-year Elite disposal gain.
- Revenue rose 10%, driven by recurring subscriptions and transaction growth across the three main professional segments.
- Adjusted EBITDA increased 10% to USD 651 million, supported by professional-segment growth and higher Reuters generative AI content licensing revenue.
- Adjusted EBITDA margin slipped to 35.5% from 35.8%, with higher technology and other costs weighing on professional-segment profitability.
- Adjusted earnings benefited from EBITDA growth, partly offset by higher internally developed software amortization and net interest expense.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
South Korea’s current account surplus in September exceeded 60 billions USD for the first time, with semiconductor exports becoming the main driver
Driven by booming semiconductor exports, South Korea's current account surplus in September surged to a record high.

CoreWeave (CRWV.US) bonds hit a new low as changes in Texas data center policies impact AI cloud trading
CoreWeave (CRWV.US) bonds fell sharply on Wednesday, with some dropping to new lows.

AstraZeneca (AZN.US) reportedly receives a $10 billion acquisition offer! Shares of obesity drug developer Rhythm (RYTM.US) soar in response
According to three people familiar with the matter, AstraZeneca previously proposed to acquire obesity drug developer Rhythm Pharmaceuticals for approximately 10 billion dollars.
Goldman Sachs and Apollo in Talks to Sell 40 Billion-Dollar AI Chip Financing for SpaceX (SPCX.US), Market's Willingness to Take Over Faces Test
Goldman Sachs (GS.US) and Apollo Global Management (APO.US) are in talks with Wall Street investors to begin selling portions of a roughly $40 billion chip financing deal for SpaceX (SPCX.US).
